NCT04481191CompletedPhase 3
A Phase 3 Randomized, Open-Label, Clinical Trial to Study the Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of V260 and Inactivated Poliomyelitis Vaccine (IPV) in Chinese Healthy Infants
Merck Sharp & Dohme LLC1 site in 1 country400 target enrollmentStarted: August 25, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- Percentage of Participants Achieving Neutralizing Antibody Seroconversion to Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV
Study Overview
Brief Summary
This study will evaluate the immunogenicity and safety of concomitant administration of RotaTeq® (V260) and inactivated poliomyelitis vaccine (IPV) in Chinese infants. Its primary objective is to demonstrate that the immunogenicity of IPV in the concomitant-use group is non-inferior to the immunogenicity of IPV in the staggered-use group. The hypothesis to be tested is: The seroconversion percentage at 1 month post dose 3 for poliovirus types 1, 2, and 3 in the concomitant-use group is non-inferior to those of the staggered-use group.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 48 Days to 63 Days (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy Chinese infant 48 days to 63 days of age.
- •Infant's legally acceptable representative provides written informed consent for the study.
Exclusion Criteria
- •History of rotavirus disease, congenital gastrointestinal disorders, chronic diarrhea, failure to thrive, or abdominal surgery.
- •History of intussusception.
- •History of poliomyelitis.
- •Clinical evidence of active gastrointestinal illness. Note: Infants with gastroesophageal reflux disease [GERD] may participate in the study if the GERD is well controlled with or without medication.
- •Known or suspected impairment of immunological function, including severe combined immunodeficiency disease (SCID).
- •Has a fever, with an axillary temperature ≥37.5°C (or equivalent) at the time of vaccination or within 24 hours prior to vaccination. Note: The Visit 1 may be rescheduled after complete resolution of febrile illness.
- •Has acute disease.
- •Has underlying diseases such as cardiovascular, renal, liver, or blood disease.
- •History of known hypersensitivity to any components of rotavirus vaccine and/or IPV.
- •Uncontrolled epilepsy, encephalopathy, seizure, or other progressive neurological diseases.
- •Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
- •Resides in a household with an immunocompromised person, including individuals with congenital immunodeficiency (including SCID), human immunodeficiency virus (HIV) infection, leukemia, lymphoma, multiple myeloma, generalized malignance, chronic renal failure, organ or bone marrow transplantation, or with those receiving immunosuppressive chemotherapy including long-term systemic corticosteroids.
- •Any condition, which in the opinion of the investigator, may interfere with the evaluation of the study objectives.
- •Prior administration of any rotavirus vaccines or poliovirus vaccines.
- •Has received inactivated or recombinant vaccines within 14 days prior to Visit 1 or live vaccines within 28 days prior to Visit
- •Has received an investigational or non-registered product other than study vaccines or is planning to use such product during the study.
- •Has received immunosuppressive therapies including systemic (intramuscular, oral, or intravenous) corticosteroids. Note: Participants using non-systemic corticosteroids (e.g., topical, ophthalmic, and inhaled) are considered eligible for the study.
- •Has received a blood transfusion or blood products, including immunoglobulins or is planning to receive such product during the study.
- •Has participated in another interventional study prior to Visit 1 or expected to anytime during the study.
- •The infant's legally acceptable representative is unlikely to adhere to the study procedures, keep appointments or is planning to permanently relocate from the area prior to the completion of the study or to leave for an extended period when study visits would need to be scheduled.
- •Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an investigational site or Sponsor staff member directly involved with this study.
Outcomes
Primary Outcomes
Percentage of Participants Achieving Neutralizing Antibody Seroconversion to Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV
Time Frame: Baseline and 1 month postdose 3 of IPV (Month ~3.5)
The immunogenicity of IPV was measured using poliovirus serum neutralizing antibody assay of the National Institutes for Food and Drug Control (NIFDC), Beijing, China. Serum conversion was defined as antibody titer ≥1:8 post-vaccination in baseline seronegative participants or ≥4-fold increase in titer post-vaccination in baseline seropositive participants.
Secondary Outcomes
- Percentage of Participants Achieving Neutralizing Antibody Titers ≥1:64 for Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV(1 month postdose 3 of IPV (Month ~3.5))
- Geometric Mean Titers (GMTs) of Neutralizing Antibody to Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV(1 month postdose 3 of IPV (Month ~3.5))
- Percentage of Participants Achieving Neutralizing Antibody Titers ≥1:8 for Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV(1 month post dose 3 of IPV (Month ~3.5))
- Percentage of Participants With Solicited Injection-Site Adverse Events(Up to 7 days following each IPV vaccination)
- Percentage of Participants With Solicited Systemic Adverse Events(Up to 7 days following each RotaTeq and/or IPV vaccination)
- Percentage of Participants With Serious Adverse Events (SAEs)(Up to approximately 3.5 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)Rotavirus GastroenteritisNCT02062385Merck Sharp & Dohme LLC4,040
Completed
Phase 3
A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)Rotavirus GastroenteritisNCT01600092Merck Sharp & Dohme LLC1,020
Terminated
Phase 1
A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)RotavirusNCT00836498Merck Sharp & Dohme LLC66
Completed
Phase 3
Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)RotavirusGastroenteritisNCT00496054Merck Sharp & Dohme LLC110
Completed
Phase 3
Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)Neisseria MeningitidisBacterial InfectionsVirus DiseasesNCT01553279MCM Vaccines B.V.284